lunes, 8 de mayo de 2017

Ovarian Epithelial, Fallopian Tube, Primary Peritoneal Cancer (PDQ®)—Health Professional Version - National Cancer Institute

Ovarian Epithelial, Fallopian Tube, Primary Peritoneal Cancer (PDQ®)—Health Professional Version - National Cancer Institute

National Cancer Institute

Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version



SECTIONS

Changes to This Summary (05/03/2017)

Updated statistics with estimated new cases and deaths for 2017 (cited American Cancer Society as reference 5).
Added text to state that an analysis of 2,655 patients enrolled in GOG-0182, only cytoreduction to node-visible disease that is R0 (i.e., complete surgical resection) had an independent effect on survival (cited Horowitz et al. as reference 5).
Added text to state that although more toxic, the weekly paclitaxel regimen did not adversely affect quality of life when compared with the intermittent schedule (cited Harano et al. as reference 25).
Added text to state that two phase III studies compared the outcome of standard primary cytoreductive surgery (PCS) with that of neoadjuvant chemotherapy followed by interval cytoreductive surgery; both studies demonstrated that progression-free survival and overall survival were noninferior with PCS (cited Kehoe et al. as reference 50).
Added text to state that between 2004 and 2010, a group of 87 hospitals in the United Kingdom and New Zealand enrolled 550 women with stage III or IV ovarian epithelial cancer and randomly assigned them to undergo PCS followed by six cycles of chemotherapy or to receive primary (neoadjuvant) chemotherapy for three cycles, followed by surgery and three additional cycles of chemotherapy (cited level of evidence 1iiA).
Added text to state that these studies and additional observational and partially published phase III studies have led to the publication of a Clinical Practice Guideline on behalf of the Society of Gynecologic Oncology and the American Society of Clinical Oncology (cited Wright et al. as reference 51).
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: May 3, 2017

No hay comentarios:

Publicar un comentario